Enzon Pharma Inc (ENZN) 0.3801 $ENZN OTC Market
Post# of 273254
Posted On: 09/21/2016 7:19:41 AM
Enzon Pharma Inc (ENZN) 0.3801 $ENZN
OTC Markets Group Welcomes Enzon Pharmaceuticals, Inc. to OTCQX
PR Newswire - Tue Aug 09, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Enzon Pharmaceuticals, Inc. (OTCQX: ENZN), a pharmaceutical company that receives royalty revenues for licensing arrangements with other companies, has qualified to trade on the OTCQX® Best Market.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Delaware Law by the Board of Enzon Pharmaceuticals Inc.
PR Newswire - Wed Jan 27, 11:24AM CST
Levi & Korsinsky announces it has commenced an investigation of Enzon Pharmaceuticals Inc. (NASDAQ: ENZN) concerning possible breaches of Delaware law by the board of directors of the company. To obtain additional information, go to:
Cellceutix Retains Former Durata Executive Ronald Trust as Regulatory Affairs Consultant
Marketwired - Mon Nov 30, 6:30AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, announced today that Ronald Trust, PhD, MBA, has been retained as a consultant to the Company to oversee regulatory affairs pertaining to the planned Brilacidin Phase 3 program for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), among other responsibilities.
AGN: 238.67 (-6.62)
Biotechnology Stocks Technical Study -- Exelixis, XOMA Corp., Enzon Pharma, Peregrine Pharma, and StemCells
PR Newswire - Mon Sep 21, 7:50AM CDT
Equity Research Institute has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), XOMA Corporation (NASDAQ: XOMA), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and StemCells Inc. (NASDAQ: STEM). Free research report on Exelixis can be accessed at https://www.erionline.net/EXEL.pdf On Friday, September 18, 2015, the NASDAQ Composite ended at 4,827.23, down 1.36%, the Dow Jones Industrial Average declined 1.74%, to finish the day at 16,384.79, and the S&P 500 closed at 1,958.03, down 1.62%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
STEM: 1.37 (-0.03), PPHM: 0.38 (+0.01), XOMA: 0.51 (-0.03), EXEL: 14.16 (+0.52)
Guidance & Quarterly Review on Four Biotech Companies
ACCESSWIRE - Fri Aug 14, 6:00AM CDT
NEW YORK, NY / ACCESSWIRE / August 14, 2015 / Four biotechnology companies reported earnings last week. These companies include Synta Pharmaceuticals (NASDAQ: SNTA), TransEnterix, Inc., (NYSE-MKT: TRXC), Xoma Corp (NASDAQ: XOMA) and Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN).
SNTA: 0.34 (+0.07), TRXC: 1.49 (+0.02), XOMA: 0.51 (-0.03)
Technical Coverage on Biotechnology Equities -- Achillion Pharma, CTI BioPharma, Enzon Pharma, Discovery Laboratories, and Pacific Biosciences of California
PR Newswire - Mon Jul 20, 8:10AM CDT
Equity Research Institute has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), CTI BioPharma Corporation (NASDAQ: CTIC), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Discovery Laboratories Inc. (NASDAQ: DSCO), and Pacific Biosciences of California Inc. (NASDAQ: PACB). Free research report on Achillion Pharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=ACHN On Friday, July 17, 2015, the NASDAQ Composite ended at 5,210.14, up 0.91%, the Dow Jones Industrial Average declined 0.19%, to finish the day at 18,086.45, and the S&P 500 closed at 2,126.64, up 0.11%. The losses were broad based as six out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
PACB: 8.80 (+0.30), ACHN: 7.96 (+0.15), CTIC: 0.36 (unch), DSCO: 3.50 (-0.36)
Technical Scrutiny on Biotech Stocks -- ARIAD Pharma, Array BioPharma, Enzon Pharma, Ironwood Pharma, and Regulus Therapeutics
PR Newswire - Tue May 12, 7:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
IRWD: 15.10 (+0.21), RGLS: 3.44 (+0.16), ARIA: 12.90 (+0.79), ARRY: 3.64 (-0.06)
Health of Health Care Stocks: Complementary Research on Enzon Pharmaceuticals, Durect Corporation, Vertex Pharmaceuticals, Advaxis, and Omnicare
PR Newswire - Fri Apr 24, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
OCR: 97.90 (-0.02), ADXS: 10.56 (+0.15), VRTX: 91.69 (+0.43), DRRX: 1.75 (+0.07)
Nasdaq stocks posting largest volume increases
AP - Thu Apr 23, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CALI: 2.47 (-0.01), PCMI: 19.20 (+0.88), URRE: 1.41 (-0.05), HMTV: 12.67 (+0.07), SCYX: 3.69 (+0.19), ARTW: 2.98 (-0.03), PKT: 11.50 (+0.02), PLMT: 19.25 (unch), MNRK: 18.49 (-1.37)
Most active Nasdaq-traded stocks
AP - Thu Apr 23, 5:05PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 16.92 (-0.03), AMD: 6.17 (+0.01), FB: 128.64 (-0.01), BRCM: 54.67 (+0.17), TXN: 69.18 (-0.36), CMCSK: 58.00 (-1.69), MSFT: 56.81 (-0.12), INTC: 37.14 (-0.02), VLTC: 2.60 (-0.21), CMCSA: 66.23 (+0.38), AAPL: 113.57 (-0.01), CSCO: 31.10 (+0.08)
Key Trends in the Pharmaceutical and Nutritional Supplement Industries Outperforming Other Industries as Increase in Pharma Grade Products & Supplements Grow Globally
PR Newswire - Wed Apr 22, 7:35AM CDT
The Worldwide nutritional supplement market, segmented into groups such as vitamins, pharma grade supplements, protein supplements, probiotics, fish oils, blended supplements, is driven by factors such as increasing global health consciousness and growing consumer income. Some analyst forecasts that the global dietary supplements market was valued at $60 Billion in 2014 and is expected to reach $80 Billion by 2020. Nutrition & Pharma Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Vitamin Shoppe (NYSE:VSI), Herbalife Ltd. (NYSE: HLF) and Enzon Pharmaceuticals (NASDAQ: ENZN)
HLF: 60.45 (-0.99), VSI: 26.37 (-0.29), GNC: 20.15 (-0.57), MYL: 41.26 (-0.23), TEVA: 50.36 (-0.34)
A Look at the Health of the HealthCare Sector: Complementary Research on Horizon Pharma, Enzon Pharmaceuticals, Momenta Pharmaceuticals, Athersys, and Pernix Therapeutics
PR Newswire - Tue Apr 21, 9:46AM CDT
Editor Note: For more information about this release, please scroll to bottom.
PTX: 0.58 (-0.02), HZNP: 18.91 (-0.21), ATHX: 1.98 (+0.01), MNTA: 11.99 (+0.21)
OTC Markets Group Welcomes Enzon Pharmaceuticals, Inc. to OTCQX
PR Newswire - Tue Aug 09, 6:00AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Enzon Pharmaceuticals, Inc. (OTCQX: ENZN), a pharmaceutical company that receives royalty revenues for licensing arrangements with other companies, has qualified to trade on the OTCQX® Best Market.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Delaware Law by the Board of Enzon Pharmaceuticals Inc.
PR Newswire - Wed Jan 27, 11:24AM CST
Levi & Korsinsky announces it has commenced an investigation of Enzon Pharmaceuticals Inc. (NASDAQ: ENZN) concerning possible breaches of Delaware law by the board of directors of the company. To obtain additional information, go to:
Cellceutix Retains Former Durata Executive Ronald Trust as Regulatory Affairs Consultant
Marketwired - Mon Nov 30, 6:30AM CST
Cellceutix Corporation (OTC: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, announced today that Ronald Trust, PhD, MBA, has been retained as a consultant to the Company to oversee regulatory affairs pertaining to the planned Brilacidin Phase 3 program for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), among other responsibilities. AGN: 238.67 (-6.62)
Biotechnology Stocks Technical Study -- Exelixis, XOMA Corp., Enzon Pharma, Peregrine Pharma, and StemCells
PR Newswire - Mon Sep 21, 7:50AM CDT
Equity Research Institute has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), XOMA Corporation (NASDAQ: XOMA), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), and StemCells Inc. (NASDAQ: STEM). Free research report on Exelixis can be accessed at https://www.erionline.net/EXEL.pdf On Friday, September 18, 2015, the NASDAQ Composite ended at 4,827.23, down 1.36%, the Dow Jones Industrial Average declined 1.74%, to finish the day at 16,384.79, and the S&P 500 closed at 1,958.03, down 1.62%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
STEM: 1.37 (-0.03), PPHM: 0.38 (+0.01), XOMA: 0.51 (-0.03), EXEL: 14.16 (+0.52)
Guidance & Quarterly Review on Four Biotech Companies
ACCESSWIRE - Fri Aug 14, 6:00AM CDT
NEW YORK, NY / ACCESSWIRE / August 14, 2015 / Four biotechnology companies reported earnings last week. These companies include Synta Pharmaceuticals (NASDAQ: SNTA), TransEnterix, Inc., (NYSE-MKT: TRXC), Xoma Corp (NASDAQ: XOMA) and Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN).
SNTA: 0.34 (+0.07), TRXC: 1.49 (+0.02), XOMA: 0.51 (-0.03)
Technical Coverage on Biotechnology Equities -- Achillion Pharma, CTI BioPharma, Enzon Pharma, Discovery Laboratories, and Pacific Biosciences of California
PR Newswire - Mon Jul 20, 8:10AM CDT
Equity Research Institute has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), CTI BioPharma Corporation (NASDAQ: CTIC), Enzon Pharmaceuticals Inc. (NASDAQ: ENZN), Discovery Laboratories Inc. (NASDAQ: DSCO), and Pacific Biosciences of California Inc. (NASDAQ: PACB). Free research report on Achillion Pharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=ACHN On Friday, July 17, 2015, the NASDAQ Composite ended at 5,210.14, up 0.91%, the Dow Jones Industrial Average declined 0.19%, to finish the day at 18,086.45, and the S&P 500 closed at 2,126.64, up 0.11%. The losses were broad based as six out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
PACB: 8.80 (+0.30), ACHN: 7.96 (+0.15), CTIC: 0.36 (unch), DSCO: 3.50 (-0.36)
Technical Scrutiny on Biotech Stocks -- ARIAD Pharma, Array BioPharma, Enzon Pharma, Ironwood Pharma, and Regulus Therapeutics
PR Newswire - Tue May 12, 7:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
IRWD: 15.10 (+0.21), RGLS: 3.44 (+0.16), ARIA: 12.90 (+0.79), ARRY: 3.64 (-0.06)
Health of Health Care Stocks: Complementary Research on Enzon Pharmaceuticals, Durect Corporation, Vertex Pharmaceuticals, Advaxis, and Omnicare
PR Newswire - Fri Apr 24, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
OCR: 97.90 (-0.02), ADXS: 10.56 (+0.15), VRTX: 91.69 (+0.43), DRRX: 1.75 (+0.07)
Nasdaq stocks posting largest volume increases
AP - Thu Apr 23, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
CALI: 2.47 (-0.01), PCMI: 19.20 (+0.88), URRE: 1.41 (-0.05), HMTV: 12.67 (+0.07), SCYX: 3.69 (+0.19), ARTW: 2.98 (-0.03), PKT: 11.50 (+0.02), PLMT: 19.25 (unch), MNRK: 18.49 (-1.37)
Most active Nasdaq-traded stocks
AP - Thu Apr 23, 5:05PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 16.92 (-0.03), AMD: 6.17 (+0.01), FB: 128.64 (-0.01), BRCM: 54.67 (+0.17), TXN: 69.18 (-0.36), CMCSK: 58.00 (-1.69), MSFT: 56.81 (-0.12), INTC: 37.14 (-0.02), VLTC: 2.60 (-0.21), CMCSA: 66.23 (+0.38), AAPL: 113.57 (-0.01), CSCO: 31.10 (+0.08)
Key Trends in the Pharmaceutical and Nutritional Supplement Industries Outperforming Other Industries as Increase in Pharma Grade Products & Supplements Grow Globally
PR Newswire - Wed Apr 22, 7:35AM CDT
The Worldwide nutritional supplement market, segmented into groups such as vitamins, pharma grade supplements, protein supplements, probiotics, fish oils, blended supplements, is driven by factors such as increasing global health consciousness and growing consumer income. Some analyst forecasts that the global dietary supplements market was valued at $60 Billion in 2014 and is expected to reach $80 Billion by 2020. Nutrition & Pharma Companies in focus today are: Axxess Pharma Inc. (OTC: AXXE), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Vitamin Shoppe (NYSE:VSI), Herbalife Ltd. (NYSE: HLF) and Enzon Pharmaceuticals (NASDAQ: ENZN)
HLF: 60.45 (-0.99), VSI: 26.37 (-0.29), GNC: 20.15 (-0.57), MYL: 41.26 (-0.23), TEVA: 50.36 (-0.34)
A Look at the Health of the HealthCare Sector: Complementary Research on Horizon Pharma, Enzon Pharmaceuticals, Momenta Pharmaceuticals, Athersys, and Pernix Therapeutics
PR Newswire - Tue Apr 21, 9:46AM CDT
Editor Note: For more information about this release, please scroll to bottom.
PTX: 0.58 (-0.02), HZNP: 18.91 (-0.21), ATHX: 1.98 (+0.01), MNTA: 11.99 (+0.21)
(0)
(0)Scroll down for more posts ▼